top of page
Practical Considerations for Using the TITE-BOIN Design to Handle Late-Onset Toxicity or Fast Accrual in Phase I Trials
Date: July 1, 2025 PMID: PMC12213182 Category: N/A Authors: Paste in the author's names... Abstract: 40327336 Conducting phase I trials is particularly challenging when dealing with late-onset dose-limiting toxicity (DLT) or when patient accrual is rapid relative to the DLT assessment window. In such cases, a new cohort may be ready for enrollment before the DLT assessments are complete for the current cohort, complicating dose assignment decisions. The time-to-event Bayesian
bgtaylor1
Nov 11, 20252 min read
PS-SAM: propensity-score-integrated self-adapting mixture prior to dynamically and efficiently borrow information from historical data
Date: October 2025 PMID: PMC12353383 Category: N/A Authors: Yuansong Zhao, Peng Yang, Glen Laird, Josh Chen, Ying Yuan Abstract: 40243184 There has been growing interest in incorporating historical data to improve the efficiency of randomized controlled trials (RCTs) or reduce their required sample size. A key challenge is that the patient characteristics of the historical data may differ from those of the current RCT. To address this issue, a well-known approach is to e
bgtaylor1
Nov 11, 20252 min read
Overexpression of fibroblast activation protein (FAP) in the stroma of proliferative inflammatory atrophy (PIA) and primary adenocarcinoma of the prostate
Date: August 5, 2025 PMID: PMC12534906 Category: N/A Authors: Fernanda Caramella-Pereira, Qizhi Zheng, Jessica L Hicks, Sujayita Roy, Tracy Jones, Martin Pomper, Lizamma Antony, Alan K Meeker, Srinivasan Yegnasubramanian, Angelo M De Marzo, W Nathaniel Brennen Abstract: 40187966 Fibroblast activation protein (FAP) is a serine protease upregulated at sites of tissue remodelling and cancer that represents a promising therapeutic and molecular imaging target. In prostate cancer,
bgtaylor1
Nov 11, 20252 min read
bottom of page